Searchable abstracts of presentations at key conferences in endocrinology

ea0077p131 | Nursing Practice | SFEBES2021

The value of dual energy X-ray absorptiometry (DXA) scan in patients at low risk of fragility fracture

Notey Rajinder , Buensalido Mayla , Del Rosario Ann , Gittoes Neil , Criseno Sherwin

Background: University Hospitals Birmingham NHS Foundation Trust offers a comprehensive bone health assessment, through the Fracture Liaison Service (FLS), to individuals who sustain fragility fracture/s. Patients requiring assessment are identified daily through admissions from Accident and Emergency and Trauma and Orthopaedics. A bone density scan is requested for further investigations according to the FRAX tool to identify more accurately their fracture risk and to help de...

ea0081p21 | Adrenal and Cardiovascular Endocrinology | ECE2022

Time from referral to definitive treatment in Cushing’s syndrome

Coulden Amy , Aylwin Simon , Flanagan Daniel , Mamoojee Yaasir , Pal Aparna , Gittoes Neil , Gleeson Helena

Rapid diagnosis and treatment of Cushing’s syndrome (CS) is essential for good outcomes. Current standards for appropriate timelines for referral are under review by NHSE. Data are required to substantiate standard setting. Knowledge of current referral pathways/processes are required to explore delays in accessing definitive surgical treatment. An audit of referral processes at Queen Elizabeth Hospital Birmingham was undertaken and further expanded to 4 additional tertia...

ea0050p050 | Bone and Calcium | SFEBES2017

Discontinuation of denosumab–real world experience from a single centre

Venkataraman Hema , Dar Shuja , Hiwot Tarek , Criseno Sherwin , Hassan-Smith Zaki , Gittoes Neil

There is concern about rapid reduction in bone mineral density (BMD) and early rebound vertebral fractures following discontinuation of denosumab. Our aim was to review local experience of discontinuation of denosumab, changes in BMD and fractures in patients with osteoporosis.Methods: A retrospective analysis was conducted for patients who discontinued denosumab between March 2011 & June 2016. Denosumab withdrawal(DW) was defi...

ea0050p283 | Neuroendocrinology and Pituitary | SFEBES2017

Impact of menopause on the natural history of pre-existing prolactinomas

Santharam Sandhya , Tampourlou Metaxia , Arlt Wiebke , Ayuk John , Gittoes Neil , Mtemererwa Brian , Toogood Andrew , Karavitaki Niki

Background: It has been proposed that menopause has a beneficial effect on the natural history of hyperprolactinaemia attributed to prolactinoma. Nonetheless, series systematically assessing outcome in females with prolactinoma who have passed through menopause are very limited.Aim: To investigate the impact of menopause on prolactinomas in patients not on dopamine agonist (DA) treatment.Patie...

ea0050p050 | Bone and Calcium | SFEBES2017

Discontinuation of denosumab–real world experience from a single centre

Venkataraman Hema , Dar Shuja , Hiwot Tarek , Criseno Sherwin , Hassan-Smith Zaki , Gittoes Neil

There is concern about rapid reduction in bone mineral density (BMD) and early rebound vertebral fractures following discontinuation of denosumab. Our aim was to review local experience of discontinuation of denosumab, changes in BMD and fractures in patients with osteoporosis.Methods: A retrospective analysis was conducted for patients who discontinued denosumab between March 2011 & June 2016. Denosumab withdrawal(DW) was defi...

ea0050p283 | Neuroendocrinology and Pituitary | SFEBES2017

Impact of menopause on the natural history of pre-existing prolactinomas

Santharam Sandhya , Tampourlou Metaxia , Arlt Wiebke , Ayuk John , Gittoes Neil , Mtemererwa Brian , Toogood Andrew , Karavitaki Niki

Background: It has been proposed that menopause has a beneficial effect on the natural history of hyperprolactinaemia attributed to prolactinoma. Nonetheless, series systematically assessing outcome in females with prolactinoma who have passed through menopause are very limited.Aim: To investigate the impact of menopause on prolactinomas in patients not on dopamine agonist (DA) treatment.Patie...

ea0090rc3.6 | Rapid Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Discontinuation of long-term growth hormone treatment in adults with severe growth hormone deficiency: A United Kingdom web-based survey of endocrine practice

Criseno Sherwin , Gleeson Helena , Toogood Andrew , Gittoes Neil , Topping Annie , Karavitaki Niki

Introduction: In adults, treatment of growth hormone deficiency (GHD) with daily recombinant human growth hormone (GH) injections has shown to improve many clinical features associated with GHD. Currently, many adults with GHD receive GH indefinitely, even when they fail to report any obvious benefits from this treatment. Additionally, evidence on the impact of discontinuing long-term GH therapy is limited. We conducted a survey of UK endocrine clinicians (doctors and speciali...

ea0065p89 | Bone and calcium | SFEBES2019

Bone turnover marker response in patients on second line agents for osteoporosis – what is the significance of non-suppression?

Leigh Ross , Aojula Nivaran , Criseno Sherwin , Hiwot Tarek , Ayuk John , Gittoes Neil , Hassan-Smith Zaki

Background: Bone is constantly remodelling and an imbalance between bone resorption and formation can predispose to osteoporosis. Bone turnover markers (BMTs) are biochemical markers that reflect the dynamics of bone formation and resorption. Carboxy-terminal collagen crosslinks (CTx) is a bone resorption marker measured in serum which is used to monitor treatment response.Aims: The aims of the study were to determine how CTx has been used to monitor pat...

ea0049ep1051 | Pituitary - Clinical | ECE2017

Prolactinomas diagnosed after menopause: presentation and outcomes from a large specialist centre

Santharam Sandhya , Tampourlou Metaxia , Arlt Wiebke , Ayuk John , Gittoes Neil , Toogood Andrew , Webster Rachel , Karavitaki Niki

Introduction: Most prolactinomas in females are diagnosed during the years of reproductive age and the majority are microadenomas. Prolactinomas diagnosed after menopause are very rare with limited published data on their presentation and outcomes.Aim: The aim of our study was to assess the presenting clinical, biochemical and imaging findings, as well as the outcomes of women diagnosed with a prolactinoma in the post-menopausal period.<p class="abst...

ea0059p050 | Bone and calcium | SFEBES2018

Prevalence of metabolic bone disorders in patients with bony stress injuries - implications for endocrine services

Speers Christopher , Cadge Charlotte , Gittoes Neil , Gregory Kim , Hassan-Smith Zaki

Background: Bone stress injuries are typically overuse injuries associated with repetitive loading of bone and inadequate recovery. A continuum of bone stress injury from periosteal reaction to cortical fracture exists. Intrinsic and extrinsic recognised risk factors have been encapsulated within broader working consensus statements e.g. Relative Energy Deficiency in Sport (RED-S). There is uncertainty as to the appropriate metabolic work-up for such patients.<p class="abs...